Compare · NVO vs QUCY
NVO vs QUCY
Side-by-side comparison of Novo Nordisk A/S (NVO) and Mainz Biomed N.V. (QUCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and QUCY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 8782.5x QUCY ($24.6M).
- QUCY has been more active in the news (9 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for QUCY).
- Company
- Novo Nordisk A/S
- Mainz Biomed N.V.
- Price
- $48.78+1.22%
- $1.08-1.82%
- Market cap
- $215.95B
- $24.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 9
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest QUCY
- Mainz Biomed N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mainz Biomed N.V. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Quantum Cyber Completes Acquisition of U.S.-Based Manufacturing Facility in Bridgeport, Connecticut
- Quantum Cyber Reports Approximately $2 Million of Purchase Orders for Quantum Drone Corporation
- New insider Buffalino Louis R. claimed no ownership of stock in the company (SEC Form 3)
- Quantum Cyber Completes Confidential Submission to U.S. Army Program
- SEC Form 4 filed by Director O'Rourke Peter
- Quantum Cyber Targets Annual Production Capacity of 100,000 Drones combining Kamikaze, Interceptor, Surveillance, VTOL and long-range Phantom 950 at Planned Bridgeport, Connecticut Manufacturing Facility
- Quantum Cyber Addresses Short Seller Biased Report
- Quantum Cyber Introduces PHANTOM-950 Long-Range Autonomous UAS Platform in Development